Myriad Genetics | MYGN - Equity Capital And Reserves


Myriad Genetics reported $372.8M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Agilent USD 6.74B 371M Sep/2025
Becton, Dickinson and Co. USD 25.39B 82M Sep/2025
Bio-Rad Laboratories USD 6.74B 391.9M Sep/2025
Bruker USD 2.49B 625.6M Sep/2025
Danaher USD 52.53B 1.46B Dec/2025
Exact Sciences USD 2.5B 32M Sep/2025
Hologic USD 5.25B 197.2M Dec/2025
Illumina USD 2.38B 123M Sep/2025
J&J USD 78.47B 0 Sep/2025
Mettler Toledo International USD -249.2M 9.59M Sep/2025
Myriad Genetics USD 372.8M 15.3M Sep/2025
Quest Diagnostics USD 7.26B 30M Sep/2025
Quidel USD 2.04B 756.3M Sep/2025
Repligen USD 442.96M 1.62B Sep/2025
Revvity USD 7.38B 180.27M Sep/2025
Standard Biotools USD 399.66M 24.88M Sep/2025
Thermo Fisher Scientific USD 53.54B 2.38B Dec/2025
Veracyte USD 1.26B 36.61M Sep/2025
Waters USD 2.33B 170.88M Sep/2025